Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.39 |
| ▸ | LIPC | P11150 | 1/20 | 0.39 |
| ▸ | FSCN1 | Q16658 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4691826 | 0.89 | HPGD (0.43) | ALDH1A1KDM4EHPGDHTTSMN1; SMN2 | |
| SCHEMBL14107109 | 0.88 | DRD3 (0.39) | NAMPTALDH1A1KDM4EHPGDHTT | |
| SCHEMBL4689365 | 0.86 | POLB (0.48) | ALDH1A1POLBCHRM1 | |
| SCHEMBL4688350 | 0.85 | MAPK3 (0.43) | ALDH1A1KDM4EHPGDHTTSMN1; SMN2 | |
| SCHEMBL4326204 | 0.85 | SLC22A2 (0.42) | ALDH1A1KDM4EHPGDHTTFSCN1 | |
| SCHEMBL4688507 | 0.84 | SMN1; SMN2 (0.45) | ALDH1A1KDM4EHPGDHTTSMN1; SMN2 | |
| SCHEMBL4320687 | 0.83 | KDM4E (0.42) | ALDH1A1KDM4EHPGDHTTKCNH2 | |
| SCHEMBL4326547 | 0.82 | DRD3 (0.36) | NAMPTALDH1A1KDM4EHPGDHTT | |
| SCHEMBL4320857 | 0.82 | DRD3 (0.36) | NAMPTALDH1A1KDM4EHPGDHTT | |
| SCHEMBL4319289 | 0.81 | P2RX7 (0.42) | ALDH1A1KDM4EHPGDHTTLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539714-B1 | 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7399763-B2 | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20050288293-A1 | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288293-A1 | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors | TYMP, TOP1, REV1 | NAMPT 1593/4885ALDH1A1 1715/4885KDM4E 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.